Design, power, and interpretation of studies in the standard murine model of ALS

Cited by (503)

Items 101–200 of 503

1. Efficacy of HIV Postexposure Prophylaxis: Systematic Review and Meta-analysis of Nonhuman Primate Studies
   Cadi Irvine, Kieren J. Egan, Zara Shubber, Koen K. A. Van Rompay, Rachel L. Beanland, Nathan Paul Ford · 2015 · Clinical Infectious Diseases
2. Metformin Treatment Has No Beneficial Effect in a Dose-Response Survival Study in the SOD1G93A Mouse Model of ALS and Is Harmful in Female Mice
   Hannah Kaneb, Paul S. Sharp, Nazanin Rahmani Kondori, Dominic J. Wells · 2011 · PLoS ONE
3. A New AAV10-U7-Mediated Gene Therapy Prolongs Survival and Restores Function in an ALS Mouse Model
   Maria Grazia Biferi, Mathilde Cohen-Tannoudji, Ambra Cappelletto, Benoit Giroux, Marianne Roda, Stéphanie Astord, Thibaut Marais, Corinne Bos, Thomas Voït, Arnaud Ferry et al. · 2017 · Molecular Therapy
4. Absence of toll-like receptor 4 (TLR4) extends survival in the hSOD1G93A mouse model of amyotrophic lateral sclerosis
   Lee, Jia Y, Lee, John D, Phipps, Simon, Noakes, Peter G, Woodruff, Trent M · 2015 · Journal of Neuroinflammation
5. Animal Models of Neurological Disorders
   Marie‐Françoise Chesselet, Stanley Thomas Carmichael · 2012 · Neurotherapeutics
6. Dysregulation of intracellular copper homeostasis is common to transgenic mice expressing human mutant superoxide dismutase-1s regardless of their copper-binding abilities
   Eiichi Tokuda, Eriko Okawa, Shunsuke Watanabe, Shin-ichi Ono, Stefan L. Marklund · 2013 · Neurobiology of Disease
7. Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets
   Bespalov, Anton, Steckler, Thomas, Altevogt, Bruce, Koustova, Elena, Skolnick, Phil, Deaver, Daniel, Millan, Mark J., Bastlund, Jesper F., Doller, Dario, Witkin, Jeffrey et al. · 2016 · Nature Reviews Drug Discovery
8. The clinical trial landscape in amyotrophic lateral sclerosis—Past, present, and future
   Heike J. Wobst, Korrie L. Mack, Dean G. Brown, Nicholas J. Brandon, James Shorter · 2020 · Medicinal Research Reviews
9. Analysis of animal-to-human translation shows that only 5% of animal-tested therapeutic interventions obtain regulatory approval for human applications
   Benjamin Victor Ineichen, Eva Furrer, Servan Grüninger, Wolfgang Emanuel Zürrer, Malcolm Robert Macleod · 2024 · PLoS Biology
10. Overexpression of ferroptosis defense enzyme Gpx4 retards motor neuron disease of SOD1G93A mice
    Liuji Chen, Ren Na, Kirsten Danae McLane, Cody S. Thompson, Ju Gao, Xinglong Wang, Qitao Ran · 2021 · Scientific Reports
11. No Benefit from Chronic Lithium Dosing in a Sibling-Matched, Gender Balanced, Investigator-Blinded Trial Using a Standard Mouse Model of Familial ALS
    Alan Gill, Joshua D. Kidd, Fernando G. Vieira, Kenneth Thompson, Steven Perrin · 2009 · PLoS ONE
12. Mouse models of neurodegeneration: Know your question, know your mouse
    Elizabeth Fisher, David M. Bannerman · 2019 · Science Translational Medicine
13. Alterations in the motor neuron–renshaw cell circuit in the Sod1G93A mouse model
    Hanna Wootz, Eileen FitzSimons‐Kantamneni, Martin Larhammar, Travis M. Rotterman, Anders Enjin, Kalicharan Patra, Elodie André, Brigitte van Zundert, Klas Kullander, Francisco J. Álvarez · 2012 · The Journal of Comparative Neurology
14. Guanabenz Treatment Accelerates Disease in a Mutant SOD1 Mouse Model of ALS
    Fernando G. Vieira, Qinggong Ping, Andy J. Moreno, Joshua D. Kidd, Kenneth Thompson, Bingbing Jiang, John M. Lincecum, Monica Z. Wang, Gerard S. De Zutter, Valerie R. Tassinari et al. · 2015 · PLoS ONE
15. Cerium oxide nanoparticles with antioxidant properties ameliorate strength and prolong life in mouse model of amyotrophic lateral sclerosis
    William E. DeCoteau, Karin L. Heckman, Ana Yesenia Estevez, Kenneth J. Reed, Wendi Costanzo, David Sandford, Paige E. Studlack, Jennifer Clauss, Elizabeth Nichols, Jennifer Lipps et al. · 2016 · Nanomedicine Nanotechnology Biology and Medicine
16. Animal models of Huntington's disease for translation to the clinic: Best practices
    Liliana Menalled, Daniela Brunner · 2014 · Movement Disorders
17. Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development
    Adam L. Boxer, Michael Gold, Edward D. Huey, Fen‐Biao Gao, Edward A. Burton, Tiffany W. Chow, Aimee W. Kao, Blair R. Leavitt, Bruce T. Lamb, Megan E. Grether et al. · 2012 · Alzheimer s & Dementia
18. Neuroscience: Standard model
    Jim Schnabel · 2008 · Nature
19. Enhancing translation: Guidelines for standard pre-clinical experiments in mdx mice
    Raffaella Willmann, Annamaria De Luca, Michael G Benatar, Miranda D. Grounds, Judith Dubach, Jean‐Marc Raymackers, Kanneboyina Nagaraju · 2011 · Neuromuscular Disorders
20. The new paradigm in animal testing – “3Rs alternatives”
    Wen Tsin Poh, Johnson Stanslas · 2024 · Regulatory Toxicology and Pharmacology
21. Randomized Block Experimental Designs Can Increase the Power and Reproducibility of Laboratory Animal Experiments
    Michael F. W. Festing · 2014 · ILAR Journal
22. Mouse models rarely mimic the transcriptome of human neurodegenerative diseases: A systematic bioinformatics-based critique of preclinical models
    Burns, Terry C., Li, Matthew D., Mehta, Swapnil, Awad, Ahmed J., Morgan, Alexander A. · 2015 · European Journal of Pharmacology
23. How Many Ways Can Mouse Behavioral Experiments Go Wrong? Confounding Variables in Mouse Models of Neurodegenerative Diseases and How to Control Them
    Heather Macintosh Schellinck, David P. Cyr, Richard E. Brown · 2010 · Advances in the study of behavior
24. Reduction of cholesterol synthesis in the mouse brain does not affect amyloid formation in Alzheimer's disease, but does extend lifespan
    Halford, Rebekkah W., Russell, David W. · 2009 · Proceedings of the National Academy of Sciences
25. PPAR gamma activation is neuroprotective in a Drosophila model of ALS based on TDP-43
    Archi Joardar, Judith Menzl, Taylor Catherine Podolsky, Ernesto Manzo, Patricia S. Estes, Sarah Ashford, Daniela C. Zarnescu · 2014 · Human Molecular Genetics
26. New Insights on the Mechanisms of Disease Course Variability in ALS from Mutant SOD1 Mouse Models
    Giovanni Nardo, Maria Chiara Trolese, Massimo Tortarolo, Antonio Vallarola, Mattia Freschi, Laura Pasetto, Valentina Bonetto, Caterina Bendotti · 2016 · Brain Pathology
27. Safety and efficacy of human embryonic stem cell-derived astrocytes following intrathecal transplantation in SOD1G93A and NSG animal models
    Michal Izrael, Shalom Guy Slutsky, Tamar Admoni, Louisa Cohen, Avital Granit, Arik Hasson, Joseph Itskovitz‐Eldor, Lena Krush Paker, Graciela Kuperstein, Neta Lavon et al. · 2018 · Stem Cell Research & Therapy
28. Nicotinamide Riboside Enhances Mitochondrial Proteostasis and Adult Neurogenesis through Activation of Mitochondrial Unfolded Protein Response Signaling in the Brain of ALS SOD1G93A Mice
    Qi Zhou, Lei Zhu, Weiwen Qiu, Yue Liu, Fang Yang, Wenzhi Chen, Renshi Xu · 2019 · International Journal of Biological Sciences
29. Ex vivo gene therapy for the treatment of neurological disorders
    Genevíève Gowing, Soshana P. Svendsen, Clive N. Svendsen · 2017 · Progress in brain research
30. Skeletal Muscle in ALS: An Unappreciated Therapeutic Opportunity?
    Silvia Scaricamazza, Illari Salvatori, Alberto Ferri, Cristiana Valle · 2021 · Cells
31. Sphingolipid Metabolism Is Dysregulated at Transcriptomic and Metabolic Levels in the Spinal Cord of an Animal Model of Amyotrophic Lateral Sclerosis
    Alexandre Henriques, Vincent Croixmarie, Alexandra Bouscary, Althéa Mosbach, Céline Keime, Claire Boursier-Neyret, Bernard Walter, Michael Spedding, Jean‐Philippe Loeffler · 2018 · Frontiers in Molecular Neuroscience
32. Fingolimod: A Disease-Modifier Drug in a Mouse Model of Amyotrophic Lateral Sclerosis
    Potenza, Rosa Luisa, De Simone, Roberta, Armida, Monica, Mazziotti, Valentina, Pèzzola, Antonella, Popoli, Patrizia, Minghetti, Luisa · 2016 · Neurotherapeutics
33. Differential expression of microRNAs and other small RNAs in muscle tissue of patients with ALS and healthy age-matched controls
    Anja Kovanda, Lea Leonardis, Janez Zidar, Blaž Koritnik, Leja Dolenc‐Grošelj, Stanislava Ristic Kovacic, Tomaž Curk, Boris Rogelj · 2018 · Scientific Reports
34. FTD and ALS—translating mouse studies into clinical trials
    Lars Matthias Ittner, Glenda Margaret Halliday, Jillian J. Kril, Jürgen Götz, John R. Hodges, Matthew C. Kiernan · 2015 · Nature Reviews Neurology
35. Motor neuron disease: systematic reviews of treatment for ALS and SMA
    Richard W. Orrell · 2009 · British Medical Bulletin
36. MicroRNA in skeletal muscle development, growth, atrophy, and disease
    Anja Kovanda, Tadeja Režen, Boris Rogelj · 2014 · Wiley Interdisciplinary Reviews - RNA
37. S[+] Apomorphine is a CNS penetrating activator of the Nrf2-ARE pathway with activity in mouse and patient fibroblast models of amyotrophic lateral sclerosis
    Richard J. Mead, Adrian Higginbottom, Scott P. Allen, Janine Kirby, Ellen Bennett, Siân C. Barber, Paul Roy Heath, Antonio Coluccia, Neelam Patel, Iain B. Gardner et al. · 2013 · Free Radical Biology and Medicine
38. Amyotrophic Lateral Sclerosis: New Insights into Underlying Molecular Mechanisms and Opportunities for Therapeutic Intervention
    Mauro Cozzolino, Maria Grazia Pesaresi, Valeria Gerbino, Julian Großkreutz, Maria Teresa Carrı̀ · 2012 · Antioxidants and Redox Signaling
39. SOD1 silencing in motoneurons or glia rescues neuromuscular function in ALS mice
    Elisabeth Dirren, Julianne Aebischer, Cylia Rochat, Chris L. Towne, Bernard Laurent Schneider, Patrick Aebischer · 2015 · Annals of Clinical and Translational Neurology
40. Differences in protein quality control correlate with phenotype variability in 2 mouse models of familial amyotrophic lateral sclerosis
    Marianna Marino, Simonetta Papa, V. Crippa, Giovanni Nardo, Marco Peviani, Cristina Cheroni, Maria Chiara Trolese, Eliana Lauranzano, Valentina Bonetto, Angelo Poletti et al. · 2014 · Neurobiology of Aging
41. Administration of 17β-Estradiol Improves Motoneuron Survival and Down-regulates Inflammasome Activation in Male SOD1(G93A) ALS Mice
    Heitzer, Marius, Kaiser, Sarah, Kanagaratnam, Mithila, Zendedel, Adib, Hartmann, Philipp, Beyer, Cordian, Johann, Sonja · 2017 · Molecular Neurobiology
42. From the Lab to Patients: a Systematic Review and Meta-Analysis of Mesenchymal Stem Cell Therapy for Stroke
    Manoj Mathew Lalu, Joshua Ryan Montroy, Dar D Dowlatshahi, Brian Hutton, Pascale Juneau, Neil L. Wesch, Sarah Y. Zhang, Ryan N. McGinn, Dale Corbett, Duncan John Stewart et al. · 2019 · Translational Stroke Research
43. Genetic Rodent Models of Amyotrophic Lateral Sclerosis
    Ludo Van Den Bosch · 2011 · BioMed Research International
44. Sigma 1 receptor as a therapeutic target for amyotrophic lateral sclerosis
    Mireia Herrando‐Grabulosa, Núria Gaja‐Capdevila, José Miguel Vela, Xavier Navarro · 2020 · British Journal of Pharmacology
45. Current and emerging treatments for amyotrophic lateral sclerosis
    Zoccolella · 2009 · Neuropsychiatric Disease and Treatment
46. Astrocyte–neuron co-culture on microchips based on the model of SOD mutation to mimic ALS
    Anja Kunze, Sylvain Lengacher, Elisabeth Dirren, Patrick Aebischer, Pierre Julius Magistretti, Philippe Renaud · 2013 · Integrative Biology
47. MicroRNAs in Skeletal Muscle Aging: Current Issues and Perspectives
    Hwa Jin Jung, Kwang‐Pyo Lee, Ki‐Sun Kwon, Yousin Suh · 2018 · The Journals of Gerontology Series A
48. Development of MAP4 Kinase Inhibitors as Motor Neuron-Protecting Agents
    Pieter H. Bos, Emily R. Lowry, Jonathon A. Costa, Sebastian Thams, Alejandro Garcia-Diaz, Arie Zask, Hynek Wichterle, Brent R. Stockwell · 2019 · Cell chemical biology
49. Rigor or mortis: best practices for preclinical research in neuroscience.
    O. Steward, R. Balice-Gordon · 2014 · Neuron
50. CNS-targeted Viral Delivery of G-CSF in an Animal Model for ALS: Improved Efficacy and Preservation of the Neuromuscular Unit
    Alexandre Henriques, Claudia Pitzer, Tanjew Dittgen, Matthias Klugmann, Luc Dupuis, Armin Schneider · 2010 · Molecular Therapy
51. Electrophysiologic Biomarkers for Assessing Disease Progression and the Effect of Riluzole in SOD1 G93A ALS Mice
    Jia Li, Minhee Sung, Seward B. Rutkove · 2013 · PLoS ONE
52. Loss of MeCP2 in the rat models regression, impaired sociability and transcriptional deficits of Rett syndrome
    Veeraragavan, Surabi, Wan, Ying-Wooi, Connolly, Daniel R., Hamilton, Shannon M., Ward, Christopher S., Soriano, Sirena, Pitcher, Meagan R., McGraw, Christopher M., Huang, Sharon G., Green, Jennie R. et al. · 2016 · Human Molecular Genetics
53. Neuroprotection by Gene Therapy Targeting Mutant SOD1 in Individual Pools of Motor Neurons Does not Translate Into Therapeutic Benefit in fALS Mice
    Chris L. Towne, Veronica Setola, Bernard Laurent Schneider, Patrick Aebischer · 2010 · Molecular Therapy
54. Preventing the ends from justifying the means: withholding results to address publication bias in peer-review
    K. Button, Liz Bal, A. Clark, Tim Shipley · 2016 · BMC Psychology
55. Riluzole does not improve lifespan or motor function in three ALS mouse models
    Marion C. Hogg, Luise Halang, Ina Woods, Karen S. Coughlan, Jochen H.M. Prehn · 2017 · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
56. The “completely randomised” and the “randomised block” are the only experimental designs suitable for widespread use in pre-clinical research
    Michael F. W. Festing · 2020 · Scientific Reports
57. Organ-On-A-Chip Technology: An In-depth Review of Recent Advancements and Future of Whole Body-on-chip
    Rishab Driver, Shweta Mishra · 2022 · BioChip Journal
58. Diapocynin and apocynin administration fails to significantly extend survival in G93A SOD1 ALS mice
    Kari A. Trumbull, Donna M. McAllister, Mandi Gandelman, Whitney Y. Fung, Thomas K. Lew, Lucy D. Brennan, Nathan I. Lopez, Jeffrey T. Morré, Balaraman Kalyanaraman, Joseph S. Beckman · 2011 · Neurobiology of Disease
59. The Future of Preclinical Animal Models in Pharmaceutical Discovery and Development
    Jeffrey I. Everitt · 2014 · Toxicologic Pathology
60. How can we improve clinical trials in amyotrophic lateral sclerosis?
    Paul H. Gordon, Vincent Meininger · 2011 · Nature Reviews Neurology
61. Mir-17∼92 Confers Motor Neuron Subtype Differential Resistance to ALS-Associated Degeneration
    Ying-Tsen Tung, Kuan-Chih Peng, Yen‐Chung Chen, Ya-Ping Yen, Mien Chang, Sebastian Thams, Jun‐An Chen · 2019 · Cell stem cell
62. Pericytes Extend Survival of ALS SOD1 Mice and Induce the Expression of Antioxidant Enzymes in the Murine Model and in IPSCs Derived Neuronal Cells from an ALS Patient
    Coatti, Giuliana Castello, Frangini, Miriam, Valadares, Marcos C., Gomes, Juliana Plat, Lima, Natalia O., Cavaçana, Natale, Assoni, Amanda F., Pelatti, Mayra V., Birbrair, Alexander, de Lima, Antonio Carlos Pedroso et al. · 2017 · Stem Cell Reviews and Reports
63. The relationship between Bayesian motor unit number estimation and histological measurements of motor neurons in wild-type and SOD1G93A mice
    Shyuan Thieu Ngo, Fusun Baumann, Peter Ridall, Anthony N. Pettitt, Robert D. Henderson, Mark C. Bellingham, Pamela McCombe · 2012 · Clinical Neurophysiology
64. Characterization of a Novel SOD-1(G93A) Transgenic Mouse Line with Very Decelerated Disease Development
    Alexandre Henriques, Claudia Pitzer, Armin Schneider · 2010 · PLoS ONE
65. Accelerating Biomedical Discoveries through Rigor and Transparency
    J. Hewitt, Liliana L. Brown, Stephanie J. Murphy, Franziska B. Grieder, Shai D. Silberberg · 2017 · ILAR Journal
66. Rodent and fly models in behavioral neuroscience: An evaluation of methodological advances, comparative research, and future perspectives
    Thiago C. Moulin, Laura Covill, Pavel M. Itskov, Michael J. Williams, Helgi B. Schiöth · 2020 · Neuroscience & Biobehavioral Reviews
67. Motor neuron–immune interactions: the vicious circle of ALS
    Ana G. Barbeito, Pinar Mesci, Séverine Boillée · 2010 · Journal of Neural Transmission
68. Launching invasive, first‐in‐human trials against Parkinson's disease: Ethical considerations
    Jonathan Kimmelman, Alex John London, Bernard M. Ravina, Tim Ramsay, Mark Bernstein, Alan Fine, Frank W. Stahnisch, Marina Elena Emborg · 2009 · Movement Disorders
69. Experimental models for the study of neurodegeneration in amyotrophic lateral sclerosis
    Luis B. Tovar‐y‐Romo, Luz Diana Santa-Cruz, Ricardo Tapia · 2009 · Molecular Neurodegeneration
70. The microbiota restrains neurodegenerative microglia in a model of amyotrophic lateral sclerosis
    Cox, Laura M., Calcagno, Narghes, Gauthier, Christian, Madore, Charlotte, Butovsky, Oleg, Weiner, Howard L. · 2022 · Microbiome
71. Translating biological findings into new treatment strategies for amyotrophic lateral sclerosis (ALS)
    Lindsay Poppe, Laura Rué, Wim Robberecht, Ludo Van Den Bosch · 2014 · Experimental Neurology
72. Managing amyotrophic lateral sclerosis: Slowing disease progression and improving patient quality of life
    Benjamin Rix Brooks · 2009 · Annals of Neurology
73. EGFR Inhibitor Erlotinib Delays Disease Progression but Does Not Extend Survival in the SOD1 Mouse Model of ALS
    Claire E. Le Pichon, Sara L. Domínguez, Hilda O. Solanoy, Hai Ngu, Nicholas Lewin‐Koh, Mark Chen, Jeffrey Eastham‐Anderson, Ryan J. Watts, Kimberly A. Scearce-Levie · 2013 · PLoS ONE
74. The Design and Statistical Analysis of Animal Experiments: Introduction to this Issue
    Michael F. W. Festing, Timo O Nevalainen · 2014 · ILAR Journal
75. A circuit-dependent ROS feedback loop mediates glutamate excitotoxicity to sculpt the Drosophila motor system
    Jhan-Jie Peng, Shih-Han Lin, Yu‐Tzu Liu, Hsin-Chieh Lin, Tsai-Ning Li, Chi‐Kuang Yao · 2019 · eLife
76. Creatine in mouse models of neurodegeneration and aging
    Thomas Klopstock, Matthias Elstner, Andreas Bender · 2011 · Amino Acids
77. The Design of Animal Experiments
    Michael F. W. Festing · 2010
78. Recommendations for minimum information for publication of experimental pathology data: MINPEPA guidelines
    Cheryl L. Scudamore, Elizabeth J. Soilleux, Natasha A. Karp, Ken C. Smith, Richard Poulsom, C. Simon Herrington, Michael J. Day, Cory F. Brayton, Brad N. Bolon, Bruce Whitelaw et al. · 2015 · The Journal of Pathology
79. Activation of mGlu3 metabotropic glutamate receptors enhances GDNF and GLT-1 formation in the spinal cord and rescues motor neurons in the SOD-1 mouse model of amyotrophic lateral sclerosis
    Giuseppe Battaglia, Barbara Riozzi, Domenico Bucci, Luisa Di Menna, Gemma Molinaro, Simone Pallottino, Ferdinando Nicoletti, Valeria Bruno · 2014 · Neurobiology of Disease
80. Age, experience and genetic background influence treadmill walking in mice
    Christine M. Wooley, Shuqin Xing, Robert W. Burgess, Gregory A. Cox, Kevin L. Seburn · 2008 · Physiology & Behavior
81. Magnetic resonance spectroscopy of regional brain metabolite markers in FALS mice and the effects of dietary creatine supplementation
    Choi, Ji‐Kyung, Küstermann, Ekkehard, Dedeoglu, Alpaslan, Jenkins, Bruce G. · 2009 · European Journal of Neuroscience
82. Targeting angiogenin in therapy of amyotropic lateral sclerosis
    Hiroko Kishikawa, David Wu, Guo-fu Hu · 2008 · Expert Opinion on Therapeutic Targets
83. Advances in the Development of Disease-Modifying Treatments for Amyotrophic Lateral Sclerosis
    Diane Moujalled, Anthony Robert White · 2016 · CNS Drugs
84. Motor Neuron Gene Therapy: Lessons from Spinal Muscular Atrophy for Amyotrophic Lateral Sclerosis
    Andrew Paul Tosolini, James N. Sleigh · 2017 · Frontiers in Molecular Neuroscience
85. Identification of compounds protective against G93A-SOD1 toxicity for the treatment of amyotrophic lateral sclerosis
    Radhia Benmohamed, Anthony C. Arvanites, Jinho Kim, Robert J. Ferrante, Richard B. Silverman, Richard I. Morimoto, Donald R. Kirsch · 2010 · Amyotrophic Lateral Sclerosis
86. Extensive phenotypic characterisation of a human TDP-43Q331K transgenic mouse model of amyotrophic lateral sclerosis (ALS)
    Jodie Watkins, James J. P. Alix, Pamela J. Shaw, Richard J. Mead · 2021 · Scientific Reports
87. Creating Interactions between Tissue-Engineered Skeletal Muscle and the Peripheral Nervous System
    Alec S.T. Smith, Samantha L. Passey, Neil R. W. Martin, Darren J. Player, Vivek Mudera, Linda Greensmith, Mark P. Lewis · 2016 · Cells Tissues Organs
88. NRF2 as a therapeutic opportunity to impact in the molecular roadmap of ALS
    José Jiménez-Villegas, Laura Ferraiuolo, Richard J. Mead, Pamela J. Shaw, Antonio Cuadrado, Ana Isabel Rojo · 2021 · Free Radical Biology and Medicine
89. The impact of fraudulent and irreproducible data to the translational research crisis – solutions and implementation
    Schulz, Jörg B., Cookson, Mark R., Hausmann, Laura · 2016 · Journal of Neurochemistry
90. Adipose-derived Stem Cell Conditioned Media Extends Survival time of a mouse model of Amyotrophic Lateral Sclerosis
    Christine V. Fontanilla, Huiying Gu, Qingpeng Liu, Timothy Z. Zhu, Changwei Zhou, Brian H. Johnstone, Keith L. March, Robert M. Pascuzzi, Martin Rhys Farlow, Yansheng Du · 2015 · Scientific Reports
91. Development of the Digital Arthritis Index, a Novel Metric to Measure Disease Parameters in a Rat Model of Rheumatoid Arthritis
    Maria A. Lim, Brenton Louie, Daniel Ford, Kyle M. Heath, Paulyn Cha, Joe Betts-LaCroix, Pek Yee Lum, Timothy L. Robertson, Laura R. Schaevitz · 2017 · Frontiers in Pharmacology
92. Insulin-like growth factor 1 in diabetic neuropathy and amyotrophic lateral sclerosis
    Stefanie Rauskolb, Benjamin Dombert, Michael Sendtner · 2016 · Neurobiology of Disease
93. It’s Hard to Avoid Avoidance: Uncoupling the Evolutionary Connection between Plant Growth, Productivity and Stress “Tolerance”
    Albino Maggio, Ray A. Bressan, Yang Zhao, Junghoon Park, Dae‐Jin Yun · 2018 · International Journal of Molecular Sciences
94. Porcine Models of Pancreatic Cancer
    Katie L. Bailey, Mark A. Carlson · 2019 · Frontiers in Oncology
95. Effect size and statistical power in the rodent fear conditioning literature – A systematic review
    Clarissa F. D. Carneiro, Thiago C. Moulin, Malcolm Robert Macleod, Olavo B. Amaral · 2018 · PLoS ONE
96. Aligning physiology with psychology: Translational neuroscience in neuropsychiatric drug discovery
    McArthur, Robert A. · 2017 · Neuroscience & Biobehavioral Reviews
97. Cell therapy in ALS: An update on preclinical and clinical studies
    Francesca M. Sironi, Fabiola De Marchi, Letizia Mazzini, Caterina Bendotti · 2023 · Brain Research Bulletin
98. A re-assessment of a combinatorial treatment involving Schwann cell transplants and elevation of cyclic AMP on recovery of motor function following thoracic spinal cord injury in rats
    Kelli Sharp, Lisa A. Flanagan, Kelly Matsudaira Yee, Oswald Steward · 2010 · Experimental Neurology
99. The water maze paradigm in experimental studies of chronic cognitive disorders: Theory, protocols, analysis, and inference
    Minesh Kapadia, Josie Xu, Boris Šakić · 2016 · Neuroscience & Biobehavioral Reviews
100. ZNStress: a high-throughput drug screening protocol for identification of compounds modulating neuronal stress in the transgenic mutant sod1G93R zebrafish model of amyotrophic lateral sclerosis
     Alexander McGown, Pamela J. Shaw, Tennore Ramesh · 2016 · Molecular Neurodegeneration